DE69611794T2 - Stabilisierung von plasmiden - Google Patents

Stabilisierung von plasmiden

Info

Publication number
DE69611794T2
DE69611794T2 DE69611794T DE69611794T DE69611794T2 DE 69611794 T2 DE69611794 T2 DE 69611794T2 DE 69611794 T DE69611794 T DE 69611794T DE 69611794 T DE69611794 T DE 69611794T DE 69611794 T2 DE69611794 T2 DE 69611794T2
Authority
DE
Germany
Prior art keywords
repressor
plasmid
gene
expressed
essential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69611794T
Other languages
English (en)
Other versions
DE69611794D1 (de
Inventor
John Sherratt
Geraint Williams
Alexis Hanak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cobra Biologics Ltd
Original Assignee
Cobra Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cobra Therapeutics Ltd filed Critical Cobra Therapeutics Ltd
Application granted granted Critical
Publication of DE69611794D1 publication Critical patent/DE69611794D1/de
Publication of DE69611794T2 publication Critical patent/DE69611794T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69611794T 1995-09-08 1996-09-06 Stabilisierung von plasmiden Expired - Lifetime DE69611794T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9518395.0A GB9518395D0 (en) 1995-09-08 1995-09-08 Plasmid stabilization
PCT/GB1996/002208 WO1997009435A1 (en) 1995-09-08 1996-09-06 Plasmid stabilization

Publications (2)

Publication Number Publication Date
DE69611794D1 DE69611794D1 (de) 2001-03-22
DE69611794T2 true DE69611794T2 (de) 2001-08-02

Family

ID=10780420

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69611794T Expired - Lifetime DE69611794T2 (de) 1995-09-08 1996-09-06 Stabilisierung von plasmiden

Country Status (14)

Country Link
US (1) US5972708A (de)
EP (1) EP0851932B1 (de)
JP (1) JP3416888B2 (de)
KR (1) KR100356581B1 (de)
AT (1) ATE199168T1 (de)
AU (1) AU710494B2 (de)
CA (1) CA2231784C (de)
DE (1) DE69611794T2 (de)
DK (1) DK0851932T3 (de)
ES (1) ES2155620T3 (de)
GB (1) GB9518395D0 (de)
GR (1) GR3035806T3 (de)
PT (1) PT851932E (de)
WO (1) WO1997009435A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763270A (en) * 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
US6720139B1 (en) 1999-01-27 2004-04-13 Elitra Pharmaceuticals, Inc. Genes identified as required for proliferation in Escherichia coli
AU2041901A (en) * 1999-11-09 2001-06-06 Elitra Pharmaceuticals, Inc. Genes essential for microbial proliferation and antisense thereto
KR20030003221A (ko) * 1999-12-23 2003-01-09 엘리트라 파마슈티컬즈, 인코포레이티드 대장균 증식에 필요한 유전자
US6783985B1 (en) 2000-02-18 2004-08-31 Elitra Pharmaceuticals Inc. Gene disruption methodologies for drug target discovery
US20030180953A1 (en) * 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
WO2002086090A2 (en) * 2001-04-23 2002-10-31 Elitra Pharmaceuticals, Inc. Identification of essential genes of aspegillus fumigatus and methods of use
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US20030170694A1 (en) * 2001-12-21 2003-09-11 Daniel Wall Stabilized nucleic acids in gene and drug discovery and methods of use
GB0211459D0 (en) * 2002-05-18 2002-06-26 Cobra Therapeutics Ltd Plasmid stabilisation in vivo
US7700322B2 (en) 2003-10-31 2010-04-20 Novozymes A/S Method for stable gene-amplification in a bacterial host cell
GB0327056D0 (en) * 2003-11-20 2003-12-24 Cobra Biolog Ltd Plasmid maintenance
CA2619989C (en) * 2005-08-23 2014-06-17 National Research Council Of Canada Regulation of heterologous recombinant protein expression in methylotrophic and methanotrophic bacteria
WO2009073551A2 (en) * 2007-11-30 2009-06-11 Scarab Genomics Llc Lac expression system
EP2353607A1 (de) 2010-02-04 2011-08-10 BioAlliance Pharma Verwendung einer Disintegrin-Domäne eines Adamalysins zur Behandlung von Psoriasis
EP3205356A1 (de) 2016-02-10 2017-08-16 Onkoloski Institut Ljubljana Plasmidexpressionsvektor zur codierung von humanem interleukin 12 unter transkriptionskontrolle von p21-promotor und ohne antibiotikaresistenz für krebsgentherapie und andere verwendungen davon
PL3534936T3 (pl) * 2016-11-01 2021-01-25 Novo Nordisk A/S Szczepionka tolerogennego dna
US20210346306A1 (en) 2018-05-23 2021-11-11 Modernatx, Inc. Delivery of dna
CA3184474A1 (en) 2020-06-01 2021-12-09 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
EP4337177A1 (de) 2021-05-11 2024-03-20 Modernatx, Inc. Nichtvirale verabreichung von dna für verlängerte polypeptidexpression in vivo

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK410783D0 (da) * 1982-09-16 1983-09-09 Benzon A Salfred Fremgangsmade til stabilisering af plasmider
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
DK594084A (da) * 1984-12-12 1986-06-13 Novo Industri As Fremgangsmaade til stabilisering af extra-chromosomale elementer i bakterier under dyrkning
GB9215550D0 (en) * 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
US5763270A (en) * 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use

Also Published As

Publication number Publication date
US5972708A (en) 1999-10-26
DK0851932T3 (da) 2001-06-18
PT851932E (pt) 2001-07-31
ES2155620T3 (es) 2001-05-16
WO1997009435A1 (en) 1997-03-13
KR100356581B1 (ko) 2003-04-10
ATE199168T1 (de) 2001-02-15
KR19990044525A (ko) 1999-06-25
GB9518395D0 (en) 1995-11-08
AU710494B2 (en) 1999-09-23
CA2231784A1 (en) 1997-03-13
AU6885596A (en) 1997-03-27
EP0851932B1 (de) 2001-02-14
JP3416888B2 (ja) 2003-06-16
GR3035806T3 (en) 2001-07-31
JPH11511985A (ja) 1999-10-19
DE69611794D1 (de) 2001-03-22
CA2231784C (en) 2010-06-22
EP0851932A1 (de) 1998-07-08

Similar Documents

Publication Publication Date Title
DE69611794D1 (de) Stabilisierung von plasmiden
ES8603955A1 (es) Preparacion de igf y egf de humano por tecnologia de adn recombinante
HK1013847A1 (en) Gdf-1 and uog-1 proteins
ES8307297A1 (es) Proceso para la produccion microbiana de interferon fibro- blasto humano
BG101384A (en) New pesticide proteins and strains
ES8305413A1 (es) Un metodo para estabilizar y seleccionar celulas huesped quecontienen un adn recombinante
DE69024652T2 (de) Expression von tetanustoxinfragment c
ZA887773B (en) Interleukin-7
DE69637856D1 (en) Interleukin-19.
AU577810B2 (en) Cloning the gene for rabbit tumor necrosis factor polypeptide
UA27696C2 (uk) Saf-поліпептид, фрагмент днк, що кодує saf-поліпептид, рекомбінантна плазмідна днк для експресії safполіпептиду (варіанти), штам грибів streptomyces lividans, спосіб експресії saf-поліпептиду
FI924909A (fi) Biosyntetiskt foerfarande foer framstaellning av kemiska foereningar
EP0187630A3 (en) Cloned streptomyces beta-galactosidase gene
ES8504248A1 (es) Procedimiento para la fabricacion de un plasmido recombinante que contiene un aminoacido
ES8800361A1 (es) Un metodo para producir un interferon-gamma
JPS6485094A (en) Novel physiologically active polypeptide
AU2371188A (en) Cloning afl ii restriction endonuclease and methylase from anabaena flos-aquae
GEP19991877B (en) DNA Fragment Obtained from Streptomyces griseus ATCC 10137 by Molecular Cloning, Encoding SAF Polypeptide; Recombinant Plasmide DNA, Defining SAF-Polypeptide Expression (Variants); Recom¬bi¬nant Plasmide DNA pULAD3; Recombinant Plasmide DNA pULAD300; Fungus Strain Streptomyces Lividans Containing Recombinant Plasmide DNA pULAD3; SAF-Polypeptide Expression Method
JPS6485095A (en) Novel physiologically active polypeptide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ML LABORATORIES PLC, LONDON, GB

8327 Change in the person/name/address of the patent owner

Owner name: COBRA THERAPEUTICS LTD., KEELE, STAFFORDSHIRE, GB

8327 Change in the person/name/address of the patent owner

Owner name: COBRA BIOLOGICS LTD., KEELE, NEWCASTLE STAFFORDSHI